First Personal Financial Services cut its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,560 shares of the medical research company’s stock after selling 87 shares during the period. First Personal Financial Services’ holdings in Thermo Fisher Scientific were worth $3,936,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock worth $3,989,193,000 after purchasing an additional 695,079 shares during the period. BlackRock Inc. boosted its stake in shares of Thermo Fisher Scientific by 2,692.1% during the 1st quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after purchasing an additional 22,165,530 shares during the period. State Street Corp boosted its stake in shares of Thermo Fisher Scientific by 1.0% during the 1st quarter. State Street Corp now owns 16,085,954 shares of the medical research company’s stock worth $2,470,802,000 after purchasing an additional 164,367 shares during the period. Wellington Management Group LLP boosted its stake in shares of Thermo Fisher Scientific by 5.6% during the 1st quarter. Wellington Management Group LLP now owns 7,512,152 shares of the medical research company’s stock worth $1,153,867,000 after purchasing an additional 398,622 shares during the period. Finally, Morgan Stanley boosted its stake in shares of Thermo Fisher Scientific by 7.6% during the 1st quarter. Morgan Stanley now owns 4,664,882 shares of the medical research company’s stock worth $716,526,000 after purchasing an additional 327,826 shares during the period. 83.36% of the stock is owned by hedge funds and other institutional investors.

In other Thermo Fisher Scientific news, VP Seth H. Hoogasian sold 4,140 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $177.80, for a total transaction of $736,092.00. Following the sale, the vice president now owns 25,518 shares of the company’s stock, valued at $4,537,100.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Gregory J. Herrema sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The stock was sold at an average price of $176.02, for a total transaction of $5,280,600.00. Following the sale, the senior vice president now directly owns 67,016 shares in the company, valued at approximately $11,796,156.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 52,738 shares of company stock worth $9,302,112. 0.49% of the stock is owned by corporate insiders.

Several equities research analysts have issued reports on the stock. Barclays PLC reissued an “overweight” rating and issued a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Monday. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price objective for the company in a research report on Thursday, September 21st. Cowen and Company reissued an “outperform” rating and issued a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Morgan Stanley reissued an “overweight” rating and issued a $220.00 price objective on shares of Thermo Fisher Scientific in a research report on Wednesday, September 6th. Finally, Argus reissued a “buy” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, August 22nd. They noted that the move was a valuation call. One equities research analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. Thermo Fisher Scientific presently has a consensus rating of “Buy” and an average target price of $195.33.

Thermo Fisher Scientific Inc (TMO) opened at 187.32 on Tuesday. The firm’s 50-day moving average is $181.07 and its 200-day moving average is $171.15. The firm has a market cap of $73.08 billion, a price-to-earnings ratio of 32.63 and a beta of 1.05. Thermo Fisher Scientific Inc has a 52 week low of $139.07 and a 52 week high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The company had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.92 billion. During the same quarter last year, the company earned $2.03 earnings per share. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. On average, equities analysts anticipate that Thermo Fisher Scientific Inc will post $9.35 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a yield of 0.32%. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/26/thermo-fisher-scientific-inc-tmo-position-lowered-by-first-personal-financial-services.html.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.